Related Experiment Video
Updated: Nov 8, 2025

09:06
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method
Published on: October 7, 2025
100
pDriver: a novel method for unravelling personalized coding and miRNA cancer drivers
Vu V H Pham1, Lin Liu1, Cameron P Bracken2,3
1UniSA STEM, University of South Australia, Mawson Lakes, SA 5095, Australia.
Bioinformatics (Oxford, England)
|April 27, 2021
Summary
Identifying personalized cancer drivers is crucial for understanding individual patient outcomes. The novel pDriver method effectively discovers both coding and microRNA (miRNA) cancer drivers at the individual level, outperforming existing approaches.
Area of Science:
- Computational biology
- Genomics
- Cancer research
Background:
- Identifying cancer driver genes is vital for cancer research.
- Current computational methods primarily identify drivers at a population level.
- Personalized cancer treatment requires identifying drivers unique to individual patients, including microRNAs (miRNAs).
Purpose of the Study:
- To develop a novel computational method for discovering personalized cancer drivers.
- To identify both coding and miRNA cancer drivers at the individual level.
- To improve upon existing methods for personalized cancer driver discovery.
Main Methods:
- The pDriver method involves two stages: constructing patient-specific gene networks and identifying drivers based on these networks.
- pDriver was applied to five TCGA cancer datasets for validation.
- Performance was compared against state-of-the-art methods.
Main Results:
- pDriver demonstrated superior effectiveness compared to existing methods in identifying personalized cancer drivers.
- The method successfully detected miRNA cancer drivers, many of which are literature-validated.
- Personalized drivers identified in breast cancer patients were significantly enriched in relevant biological pathways.
Conclusions:
- pDriver is an effective novel method for discovering personalized coding and miRNA cancer drivers.
- The approach advances personalized cancer research by considering individual genomic variations.
- pDriver provides a valuable tool for identifying novel therapeutic targets in cancer.
Related Concept Videos
MicroRNAs
3.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
MicroRNAs
22.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.8K
Combination Therapies and Personalized Medicine
5.5K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K

